Bisphosphonates for treatment of osteoporosis: Expected benefits, potential harms, and drug holidays;Les bisphosphonates dans le traitement de l'ostéoporose: Bienfaits attendus, torts potentiels et congés thérapeutiques

Canadian Family Physician

Volumn 60, Issue 4, 2014, Pages

  Brown, Jacques P ^a   Morin, Suzanne ^b   Leslie, Msc William ^c   Papaioannou, Alexandra ^d   Cheung, Angela M ^e   Davison, Kenneth S ^f   Goltzman, David ^b   Hanley, David Arthur ^g   Hodsman, Anthony ^h   Josse, Robert ^e   Jovaisas, Algis ⁱ   Juby, Angela ^j   Kaiser, Stephanie ^k   Karaplis, Andrew ^b   Kendler, David ^l   Khan, Aliya ^d   Ngui, Daniel ^l   Olszynski, Wojciech ^m   Ste Marie, Louis Georges ⁿ   Adachi, Jonathan ^d  

^a UNIVERSITÉ LAVAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY OF VICTORIA   (Canada)

^g UNIVERSITY OF CALGARY   (Canada)

^h UNIVERSITY OF WESTERN ONTARIO   (Canada)

ⁱ UNIVERSITY OF OTTAWA   (Canada)

^j UNIVERSITY OF ALBERTA   (Canada)

^k DALHOUSIE UNIVERSITY   (Canada)

^l UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^m UNIVERSITY OF SASKATCHEWAN   (Canada)

ⁿ UNIVERSITÉ DE MONTRÉAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINOBISPHOSPHONATE; BISPHOSPHONIC ACID DERIVATIVE; UNCLASSIFIED DRUG; BONE DENSITY CONSERVATION AGENT;

ARTICLE; ATYPICAL SUBTROCHANTERIC FEMUR FRACTURE; COMORBIDITY; DIAPHYSEAL FEMUR FRACTURE; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG USE; ESOPHAGUS CANCER; FEMUR FRACTURE; FRACTURE; HEART ATRIUM FIBRILLATION; HUMAN; JAW OSTEONECROSIS; KIDNEY FUNCTION; LONG TERM CARE; OSTEOPOROSIS; RISK FACTOR; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; CHEMICALLY INDUCED; COMPLICATION; DIAPHYSIS; ESOPHAGUS TUMOR; KIDNEY FAILURE; OSTEOPOROTIC FRACTURES; RISK ASSESSMENT;

ATRIAL FIBRILLATION; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BONE DENSITY CONSERVATION AGENTS; DIAPHYSES; DIPHOSPHONATES; ESOPHAGEAL NEOPLASMS; FEMORAL FRACTURES; HUMANS; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; RENAL INSUFFICIENCY; RISK ASSESSMENT;

EID: 84904406444     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (96)

1. Davison KS, Siminoski K, Adachi JD, Hanley DA, Goltzman D, Hodsman A, et al. Bone strength: the whole is greater than the sum of its parts. Semin Arthritis Rheum 2006;36(1):22-31.
2. Papaioannou A, Wiktorowicz ME, Adachi JD, Goeree R, Papadimitropoulos E, Bedard M. Mortality, independence in living, and re-fracture one year following hip fracture in Canadians. J Obstet Gynaecol Can 2000;22(8):591-7.
3. Papaioannou A, Adachi JD, Parkinson W, Stephenson G, Bedard M. Lengthy hospitalization associated with vertebral fractures despite control for comorbid conditions. Osteoporos Int 2001;12(10):870-4.
4. Salaffi F, Cimmino MA, Malavolta N, Carotti M, Di Matteo L, Scendoni P, et al. The burden of prevalent fractures on health-related quality of life in postmenopausal women with osteoporosis: the IMOF study. J Rheumatol 2007;34(7):1551-60.
5. Pande I, Scott DL, O'Neill TW, Pritchard C, Woolf AD, Davis MJ. Quality of life, morbidity, and mortality after low trauma hip fracture in men. Ann Rheum Dis 2006;65(1):87-92.
6. Ioannidis G, Papaioannou A, Hopman WM, Akhtar-Danesh N, Anastassiades T, Pickard L, et al. Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study. CMAJ 2009;181(5):265-71.
7. Haentjens P, Magaziner J, Colon-Emeric CS, Vanderschueren D, Milisen K, Velkeniers B, et al. Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med 2010;152(6):380-90.
8. Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 2010;182(17):1864-73.
9. Beaupre LA, Morrish DW, Hanley DA, Maksymowych WP, Bell NR, Juby AG, et al. Oral bisphosphonates are associated with reduced mortality after hip fracture. Osteoporos Int 2011;22(3):983-91.
10. Sambrook PN, Cameron ID, Chen JS, March LM, Simpson JM, Cumming RG, et al. Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study. Osteoporos Int 2011;22(9):2551-6.
11. Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357:1799-809.
12. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348(9041):1535-41.
13. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280(24):2077-82.
14. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Onceyearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22.
15. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344:333-40.
16. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282(14):1344- 52.
17. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62(5):527-34.
18. Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 2008;168(8):826-31.
19. Wysowski DK. Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009;360:89-90.
20. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90(3):1294-301.
21. Odvina CV, Levy S, Rao S, Zerwekh JE, Rao DS. Unusual mid-shaft fractures during long-term bisphosphonate therapy. Clin Endocrinol (Oxf) 2010;72(2):161-8.
22. Leslie WD, Berger C, Langsetmo L, Lix LM, Adachi JD, Hanley DA, et al. Construction and validation of a simplified fracture risk assessment tool for Canadian women and men: results from the CaMos and Manitoba cohorts. Osteoporos Int 2011;22(6):1873-83.
23. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008;19(6):733-59.
24. Cremers SC, Pillai G, Papapoulos SE. Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinet 2005;44(6):551-70.
25. Greenspan SL, Emkey RD, Bone HG, Weiss SR, Bell NH, Downs RW, et al. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002;137(11):875-83.
26. Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008;43(2):222-9.
27. Neele SJ, Evertz R, De Valk-De Roo G, Roos JC, Netelenbos JC. Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women. Bone 2002;30(4):599-603.
28. Dowd R, Recker RR, Heaney RP. Study subjects and ordinary patients. Osteoporos Int 2000;11(6):533-6.
29. Siris ES, Pasquale MK, Wang Y, Watts NB. Estimating bisphosphonate use and fracture reduction among US women aged 45 years and older, 2001-2008. J Bone Miner Res 2011;26(1):3-11.
30. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22(10):1479-91.
31. Compston J. Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw. Osteoporos Int 2011;22(12):2951-61.
32. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010;28(35):5132-9.
33. Khan AA, Rios LP, Sandor GK, Khan N, Peters E, Rahman MO, et al. Bisphosphonate-associated osteonecrosis of the jaw in Ontario: a survey of oral and maxillofacial surgeons. J Rheumatol 2011;38(7):1396-402.
34. Malden N, Lopes V. An epidemiological study of alendronate-related osteonecrosis of the jaws. A case series from the south-east of Scotland with attention given to case definition and prevalence. J Bone Miner Metab 2012;30(2):171-82.
35. Aguirre JI, Akhter MP, Kimmel DB, Pingel JE, Williams A, Jorgensen M, et al. Oncologic doses of zoledronic acid induce osteonecrosis of the jaw-like lesions in rice rats (oryzomys palustris) with periodontitis. J Bone Miner Res 2012;27(10):2130-43.
36. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010;25(11):2267-94.
37. Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 2008;22:346-50.
38. Dell R, Greene D, Ott SM, Silverman S, Eisemon E, Funahashi T, et al. A retrospective analysis of all atypical femur fractures seen in a large California HMO from the years 2007 to 2009 [abstract]. J Bone Miner Res 2010:25.
39. Giusti A, Hamdy NA, Dekkers OM, Ramautar SR, Dijkstra S, Papapoulos SE. Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features. Bone 2011;48:966-71.
40. Armamento-Villareal R, Napoli N, Diemer K, Watkins M, Civitelli R, Teitelbaum S, et al. Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series. Calcif Tissue Int 2009;85(1):37-44.
41. Goh SK, Yang KY, Koh JS, Wong MK, Chua SY, Chua DT, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 2007;89(3):349-53.
42. Ing-Lorenzini K, Desmeules J, Plachta O, Suva D, Dayer P, Peter R. Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital. Drug Saf 2009;32:775-85.
43. Kwek EB, Goh SK, Koh JS, Png MA, Howe TS. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 2008;39:224-31.
44. Visekruna M, Wilson D, McKiernan FE. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 2008;93:2948-52.
45. Edwards MH, McCrae FC, Young-Min SA. Alendronate-related femoral diaphysis fracture-what should be done to predict and prevent subsequent fracture of the contralateral side? Osteoporos Int 2010;21:701-3.
46. Giusti A, Hamdy NA, Papapoulos SE. Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies. Bone 2010;47:169-80.
47. Nieves JW, Bilezikian JP, Lane JM, Einhorn TA, Wang Y, Steinbuch M, et al. Fragility fractures of the hip and femur: incidence and patient characteristics. Osteoporos Int 2010;21(3):399-408.
48. Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 2009;24:1095-102.
49. Salminen S, Pihlajamaki H, Avikainen V, Kyro A, Bostman O. Specific features associated with femoral shaft fractures caused by low-energy trauma. J Trauma 1997;43:117-22.
50. Weiss RJ, Montgomery SM, Al Dabbagh Z, Jansson KA. National data of 6409 Swedish inpatients with femoral shaft fractures: stable incidence between 1998 and 2004. Injury 2009;40(3):304-8.
51. Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 2010;95:1555-65.
52. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-99.
53. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006;296(24):2927-38.
54. Ensrud KE, Barrett-Connor EL, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial Long-term Extension. J Bone Miner Res 2004;19(8):1259-69.
55. Mellström DD, Sorensen OH, Goemaere S, Roux C, Johnson TD, Chines AA. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004;75(6):462-8.
56. Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2012;27(2):243-54.
57. Black DM, Kelly MP, Genant HK, Palermo L, Eastell R, Bucci-Rechtweg C, et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 2010;362:1761-71.
58. Compston JE. Bisphosphonates and atypical femoral fractures: a time for reflection. Maturitas 2010;65:3-4.
59. Abrahamsen B. Adverse effects of bisphosphonates. Calcif Tissue Int 2010;86:421-35.
60. Shane E. Evolving data about subtrochanteric fractures and bisphosphonates. N Engl J Med 2010;362:1825-7.
61. Nieves JW, Cosman F. Atypical subtrochanteric and femoral shaft fractures and possible association with bisphosphonates. Curr Osteoporos Rep 2010;8:34-9.
62. Schilcher J, Michaelsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011;364:1728-37.
63. Abrahamsen B, Eiken P, Eastell R. Cumulative alendronate dose and the longterm absolute risk of subtrochanteric and diaphyseal femur fractures: a registerbased national cohort analysis. J Clin Endocrinol Metab 2010;95:5258-65.
64. Lenart BA, Neviaser AS, Lyman S, Chang CC, Edobor-Osula F, Steele B, et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 2009;20(8):1353-62.
65. Girgis CM, Seibel MJ. Guilt by association? Examining the role of bisphosphonate therapy in the development of atypical femur fractures. Bone 2011;48:963-5.
66. Girgis CM, Seibel MJ. Atypical femur fractures: a complication of prolonged bisphosphonate therapy? Med J Aust 2010;193:196-8.
67. Kumm DA, Rack C, Rutt J. Subtrochanteric stress fracture of the femur following total knee arthroplasty. J Arthroplasty 1997;12:580-3.
68. Niimi R, Hasegawa M, Sudo A, Uchida A. Unilateral stress fracture of the femoral shaft combined with contralateral insufficiency fracture of the femoral shaft after bilateral total knee arthroplasty. J Orthop Sci 2008;13:572-5.
69. Schilcher J, Aspenberg P. Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate. Acta Orthop 2009;80:413-5.
70. Yang KH, Park SY, Park SW, Lee SH, Han SB, Jung WK, et al. Insufficient bilateral femoral subtrochanteric fractures in a patient receiving imatinib mesylate. J Bone Miner Metab 2010;28(6):713-8.
71. Bunning RD, Rentfro RJ, Jelinek JS. Low-energy femoral fractures associated with long-term bisphosphonate use in a rehabilitation setting: a case series. PM R 2010;2(1):76-80.
72. Park-Wyllie LY, Mamdani MM, Juurlink DN, Hawker GA, Gunraj N, Austin PC, et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 2011;305(8):783-9.
73. Wang Z, Bhattacharyya T. Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996-2007. J Bone Miner Res 2011;26:553-60.
74. Hopkins RB, Pullenayegum E, Goeree R, Adachi JD, Papaioannou A, Leslie WD, et al. Estimation of the lifetime risk of hip fracture for women and men in Canada. Osteoporos Int 2012;23(3):921-7.
75. MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 2008;148(3):197-213.
76. Health Canada. Bisphosphonate osteoporosis drugs (Aclasta, Actonel, Didrocal, Fosamax, Fosavance): small but increased risk of unusual thigh bone fractures. Ottawa, ON: Health Canada; 2011. Available from: www.hc-sc.gc.ca/ahc- asc/media/advisories-avis/-2011/2011-172-eng.php. Accessed 2012 Feb. 7.
77. Statistics Canada. Homicide offences, number and rate, by province and territory. Ottawa, ON: Statistics Canada; 2011.
78. Transport Canada. 2007 casualty rates. Ottawa, ON: Transport Canada; 2010.
79. Sørensen HT, Christensen S, Mehnert F, Pedersen L, Chapurlat RD, Cummings SR, et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ 2008;336(7648):813-6.
80. Vestergaard P, Schwartz K, Pinholt EM, Rejnmark L, Mosekilde L. Risk of atrial fibrillation associated with use of bisphosphonates and other drugs against osteoporosis: a cohort study. Calcif Tissue Int 2010;86:335-42.
81. Pazianas M, Cooper C, Wang Y, Lange JL, Russell RG. Atrial fibrillation and the use of oral bisphosphonates. Ther Clin Risk Manag 2011;7:131-44. Epub 2011 Mar. 22.
82. Barrett-Connor E, Swern AS, Hustad CM, Bone HG, Liberman UA, Papapoulos S, et al. Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials. Osteoporos Int 2012;23(1):233-45.
83. Rhee CW, Lee J, Oh S, Choi NK, Park BJ. Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis. Osteoporos Int 2012;23:247-54.
84. US Food and Drug Administration. FDA Drug Safety Communication: safety update for osteoporosis drugs, bisphosphonates, and atypical fractures. Silver Spring, MD: US Food and Drug Administration; 2010. Available from: www.fda. gov/Drugs/DrugSafety/ucm229009.htm. Accessed 2012 Feb. 10.
85. Green J, Czanner G, Reeves G, Watson J, Wise L, Beral V. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ 2010;34:c4444.
86. Cardwell CR, Abnet CC, Cantwell MM, Murray LJ. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 2010;304:657-63.
87. Dixon WG, Solomon DH. Bisphosphonates and esophageal cancer-a pathway through the confusion. Nat Rev Rheumatol 2011;7:369-72.
88. Abrahamsen B, Pazianas M, Eiken P, Russell RG, Eastell R. Esophageal and gastric cancer incidence and mortality in alendronate users. J Bone Miner Res 2012;27:679-86.
89. US Food and Drug Administration. FDA Drug Safety Communication: new contraindication and updated warning on kidney impairment for Reclast (zoledronic acid). Silver Spring, MD: US Food and Drug Administration; 2011. Available from: www.fda.gov/Drugs/DrugSafety/ucm270199.htm. Accessed 2012 Feb. 9.
90. Whitaker M, Guo J, Kehoe T, Benson G. Bisphosphonates for osteoporosis-where do we go from here? N Engl J Med 2012;366:2048-51.
91. Watts NB, Chines A, Olszynski WP, McKeever CD, McClung MR, Zhou X, et al. Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 2008;19(3):365-72.
92. Seeman E. To stop or not to stop, that is the question. Osteoporos Int 2009;20:187-95.
93. Curtis JR, Westfall AO, Cheng H, Delzell E, Saag KG. Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday. Osteoporos Int 2008;19:1613-20.
94. Cosman F, Cauley J, Eastell R, Boonen S, Palermo L, Reid I, et al. Who is at highest risk for new vertebral fractures after 3 years of annual zoledronic acid and who should remain on treatment? Paper presented at: American Society for Bone and Mineral Research Annual Meeting; 2011 Sep. 19.
95. Schwartz AV, Bauer DC, Cummings SR, Cauley JA, Ensrud KE, Palermo L, et al. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res 2010;25(5):976-82.
96. Black DM, Bauer DC, Schwartz AV, Cummings SR, Rosen CJ. Continuing bisphosphonate treatment for osteoporosis-for whom and for how long? N Engl J Med 2012;366:2051-3.